Oscar Health, Inc. (OSCR) Stock Analysis

76.0/100
Buy Not Halal Healthcare
Price $31.05
Market Cap $8.05B
52-Week Change +122.58%

Is OSCR a good investment?

Oscar Health, Inc. (OSCR) has a Plutrex AI rating of 76.0/100 as of November 08, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: ROE of 52.7% (285.9% above industry average of 13.65%) with D/E of only 0.19x ($7.49B cash + $4.1B FCF) — exceptional capital efficiency in a near-zero leverage fortress balance sheet; third consecutive guidance raise for full-year 2026 operating earnings confirms real margin improvement, not accounting artifacts. Main concern: Thin operating margin of 3.46% (10.1% below industry average of 3.85%) and net margin of 4.9% — while net margin leads peers, any 200-300 bps deterioration in medical loss ratio would eliminate profitability entirely; this risk is NOT resolved: ACA market dynamics and claims inflation remain active sector-wide headwinds, and operating margin actually appears to have compressed from the prior report's 8.0% figure to the current 3.46% — a significant apparent deterioration requiring investigation.

Investment Summary

Oscar Health (OSCR) at $30.65 presents a compelling but nuanced investment case anchored in exceptional capital efficiency, fortress-level financial health, and a continued guidance raise cycle. The company trades at a P/E of 12.87x — 28.3% below the industry average of 17.95x — while delivering ROE of 52.7% (vs industry average 13.65%), revenue growth of 72.1% (vs industry 4.32%), and net margin of 4.9% (more than double the industry average of 2.36%). The implied forward PEG of ~0.97x (12.87 P/E / 13.21% forward EPS growth) remains below 1.0, historically signaling undervaluation. The analyst consensus target of $40.33 implies 31.6% upside from current price. The Q3 2026 earnings beat ('Oscar Health, Inc. (OSCR) Beats Q3 Earnings and Revenue Estimates') and the third consecutive guidance raise for full-year operating earnings confirm that the fundamental improvement thesis is intact and not merely aspirational. The primary concern remains the deceleration of forward EPS growth (13.21% vs industry 17.97%) and persistently thin operating margins (3.46%) that leave minimal buffer against medical loss ratio deterioration. The P/E ratio dropped sharply from 22.63x in the prior report to 12.87x currently — a 43.1% compression — which is the most material metric change and materially strengthens the valuation case.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
98/100
Growth Potential
78/100
Valuation
82/100
Profitability
65/100
Debt Management
90/100
Analyst Sentiment
78/100
Technical Momentum
55/100
Insider Confidence
50/100
News Sentiment
90/100

Fundamental Analysis

OSCR's fundamental profile is dominated by its capital efficiency and balance sheet strength. ROE of 52.7% compares to an industry average of 13.65% — a 285.9% premium — achieved with D/E of only 0.19x (vs industry 0.732x). Total cash of $7.49B and FCF of $4.10B create an impenetrable financial fortress. P/E of 12.87x is 28.3% below the industry average of 17.95x, while revenue growth of 72.1% is 1,569% above the peer average of 4.32%. Net margin of 4.9% is 107.8% above the industry average of 2.36%, though operating margin of 3.46% lags the peer average of 3.85% by 10.1%. Forward EPS growth of 13.21% is the critical weakness — 26.4% below the industry average of 17.97%, meaning peers are expected to grow earnings faster near-term. The implied PEG of ~0.97x (using 12.87 P/E / 13.21% forward growth) represents approximately a 38.5% discount to the industry PEG of 1.576x, the most compelling valuation argument. The massive P/E compression from 22.63x to 12.87x since the prior report is striking and warrants investigation — this is likely the result of updated earnings data reflecting OSCR's profitability improvement rather than a multiple de-rating, as the analyst target held flat at $40.33. At $40.33 consensus target vs $30.65 current, the risk/reward remains favorable.

News Sentiment

Oscar Health is on a roll — and the numbers back it up. The tech-driven health insurance startup has just raised its full-year 2026 earnings outlook for the third time this year, signaling that management's turnaround from early losses to genuine profitability is no longer a promise but a pattern. The headline 'Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full-Year Outlook' tells investors everything they need to know: this company keeps beating expectations and setting the bar higher. The Q3 2026 earnings call transcripts ('Oscar Health, Inc. (OSCR) Q3 2026 Earnings Call Transcript' and 'What Oscar Health (OSCR) Said on Its Q3 Earnings Call') revealed a confident management team leaning into expansion — the company is actively pursuing a growth strategy targeting 2027, capitalizing on a rare opportunity as larger competitors retreat from parts of the ACA marketplace. When bigger players leave, Oscar moves in. For everyday investors, the story is simple: Oscar Health is a scrappy insurance company built on technology and smart risk management, generating $4.1 billion in annual free cash flow while sitting on $7.5 billion in cash — with almost no debt. It beat both earnings and revenue estimates in Q3, raised guidance again, and is planning to get bigger in 2027. The stock, trading around $30.65, still sits 31% below analyst consensus targets — suggesting the market hasn't fully caught up to the fundamental improvement that's clearly underway.

Risk Assessment

PRIMARY RISK: Medical loss ratio deterioration — with operating margin at only 3.46% and net margin at 4.9%, a 200-300 bps MLR increase from claims inflation, adverse selection, or regulatory changes (ACA market shifts) could eliminate profitability. This is sector-wide and not company-specific. MITIGATION: $7.49B cash and $4.1B FCF provide enormous claims reserve cushion; D/E of 0.19x means no refinancing pressure. SECONDARY RISK: Forward EPS growth deceleration — at 13.21% vs industry 17.97%, OSCR must demonstrate earnings acceleration or the valuation discount may widen rather than compress. MITIGATION: Three consecutive guidance raises and Q3 earnings beat demonstrate management credibility and execution discipline. TERTIARY RISK: Operating margin compression — if the apparent decline from 8.0% (prior report) to 3.46% (current) is real rather than a data/methodology change, this would be significant and warrants clarification. TECHNICAL RISK: Stock has drifted lower ($33.37 → $30.99 → $30.65 over ~30 days), suggesting ongoing selling pressure. Stop at $26.00 (-14.0% from $30.25 midpoint) is set at approximately 20x the new P/E denominator floor and aligns with key support where the thesis would be structurally impaired. POSITION SIZE: 2.5% maintained — appropriate for a medium-conviction buy with real margin risks.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is OSCR a halal stock?

No, Oscar Health, Inc. (OSCR) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for OSCR?

Oscar Health, Inc. (OSCR) has a Plutrex AI rating of 76.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is OSCR a good investment?

According to Plutrex AI, OSCR has a Buy rating (76.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in OSCR?

US stocks like OSCR can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in OSCR?

Plutrex AI identifies the main risks for OSCR by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about OSCR

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open OSCR in ElBarake